Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-80,236
Closed -$1.37M 22
2023
Q1
$1.37M Sell
80,236
-104,424
-57% -$2.03M 0.39% 19
2022
Q4
$3.69M Sell
184,660
-6,000
-3% -$116K 1.31% 18
2022
Q3
$4.11M Sell
190,660
-74,217
-28% -$1.78M 1.62% 19
2022
Q2
$5.22M Sell
264,877
-20,100
-7% -$421K 1.86% 17
2022
Q1
$6.7M Buy
284,977
+49,432
+21% +$1.15M 2.74% 12
2021
Q4
$6.42M Sell
235,545
-102,958
-30% -$2.94M 3% 10
2021
Q3
$9.32M Sell
338,503
-7,768
-2% -$204K 4.17% 10
2021
Q2
$9.85M Sell
346,271
-24,418
-7% -$725K 4.97% 9
2021
Q1
$12.6M Buy
370,689
+66,787
+22% +$2.55M 6.99% 8
2020
Q4
$10.1M Sell
303,902
-56,927
-16% -$2.08M 7.21% 7
2020
Q3
$11.6M Buy
360,829
+46,321
+15% +$1.33M 9.99% 4
2020
Q2
$8.66M Buy
314,508
+154,807
+97% +$3.67M 6.63% 8
2020
Q1
$2.56M Buy
159,701
+127,104
+390% +$3.01M 1.9% 13
2019
Q4
$778K Buy
+32,597
New +$663K 0.62% 15

Other funds holding INSM

Sycale Advisors's INSM Position: Q2 2023 in Review

Sycale Advisors sold out of Insmed (INSM) in Q2 2023, closing a stake of 80,236 shares — an estimated $1.37M sold.

Sycale Advisors first reported a position in INSM in Q4 2019 and held it in 14 quarters. The position peaked at $12.6M in Q1 2021. 223 funds tracked by Wall St. Rank hold INSM as of Q2 2023.

  • Sycale Advisors reported no remaining Insmed position as of Q2 2023 after selling out during the quarter.
  • Sycale Advisors sold 80,236 Insmed shares in Q2 2023, an estimated $1.37M.
  • Sycale Advisors first reported a position in Insmed in Q4 2019 and held it in 14 quarters.
  • Sycale Advisors's Insmed position peaked at $12.6M in Q1 2021.
  • 223 funds tracked by Wall St. Rank held Insmed as of Q2 2023.

Based on Sycale Advisors's 13F filing for Q2 2023, filed 9 Aug 2023.